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Abstract
Controlling pain in burn-injured patients poses a major clini-
cal challenge. Recent findings suggest that reducing the activ-
ity of the voltage-gated sodium channel Nav1.7 in primary
sensory neurons could provide improved pain control in
burn-injured patients. Here, we report that partial thickness
scalding-type burn injury on the rat paw upregulates Nav1.7
expression in primary sensory neurons 3 h following injury.
The injury also induces upregulation in phosphorylated cyclic
adenosine monophosphate response element-binding protein
(p-CREB), a marker for nociceptive activation in primary sen-
sory neurons. The upregulation in p-CREB occurs mainly in
Nav1.7-immunopositive neurons and exhibits a peak at 5 min
and, following a decline at 30min, a gradual increase from 1 h
post-injury. The Nav1.7 blocker protoxin II (ProTxII) or
morphine injected intraperitoneally 15 min before or after
the injury significantly reduces burn injury-induced spinal up-
regulation in phosphorylated serine 10 in histone H3 and
phosphorylated extracellular signal-regulated kinase 1/2,
which are both markers for spinal nociceptive processing.
Further, ProTxII significantly reduces the frequency of spon-
taneous excitatory post-synaptic currents in spinal dorsal horn
neurons following burn injury. Together, these findings indi-
cate that using Nav1.7 blockers should be considered to con-
trol pain in burn injury.
Key messages
• Burn injury upregulates Nav1.7 expression in primary sen-
sory neurons.
• Burn injury results in increased activity of Nav1.7-express-
ing primary sensory neurons.
• Inhibiting Nav1.7 by protoxin II reduces spinal nociceptive
processing.
• Nav1.7 represents a potential target to reduce pain in burn
injury.
Keywords Pain . p-ERK1/2 . Primary sensory neuron .
p-S10H3 . Spinal cord
Burn injury is associated with moderate to severe pain that
represents a significant clinical challenge [1]. The lack of effec-
tive pain management in burn-injured patients can lead to long-
term consequences including the development of anxiety, de-
pression, post-traumatic stress disorder and chronic pain [1].
Therefore, there is a need for the development of novel analge-
sic approaches to control pain in burn-injured patients.
A series of mediators produced and released during inflam-
mation that ensues after burn injury activate a major sub-set of
primary sensory neurons [1, 2]. The resulting generation and
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propagation of action potentials initiate nociceptive process-
ing in the central nervous system and lead to the experience of
pain. Voltage-gated Na+ channels (Nav), distinguished by their
alpha sub-units [3–5], are pivotal for the generation and prop-
agation of action potentials in neurons [6]. Recent studies
identified Nav1.7 as a putative key molecule for the develop-
ment of heat hypersensitivity in burn injury [4, 7, 8].
Therefore, in the present work, we examined whether specific
blockade of Nav1.7 with the selective toxin, protoxin II
(ProTxII) [9, 10], is a feasible target to reduce nociceptive
processing in burn injury.
Materials and methods
Animals, burn injury and treatment
We obeyed the UK Animals (Scientific Procedures) Act
1986, the guidelines of the revised National Institutes of
Health Guide for the Care and Use of Laboratory
Animals , Directive 2010/63/EU of the European
Parliament and of the Council on the Protection of
Animals Used for Scientific Purposes and the Committee
for Research and Ethical Issues of IASP published in
Pain , 16 (1983) 109–110 and adhered to Good
Laboratory Practice and ARRIVE guidelines. Procedures
were approved by veterinary services at all relevant insti-
tutions. Every effort was made to minimise the number of
animals used and the potential distress. Animals were
housed in climate-controlled rooms, on a 12 h light/dark
cycle, with food and water ad libitum. In total, 36 male
Sprague-Dawley rats (150-200 g), 5 male Wistar rats
(P21), 2 wild-type (WT, ~ 22 g) mice and 2 mice lacking
Nav1.7 in Nav1.8-expressing cells (Nav1.7cKO, ~ 22 g;
[5]; both types on C57BL/6 background) were used.
Burn or sham injury was induced as described previously
[11, 12]. Briefly, animals were anaesthetised by intraperito-
neal urethane (0.02 mg/g) or isoflurane (3%, for spinal cord
slice preparation) and one of the hind paws (both paws for
spinal cord slices) was immersed into 60 or 37 °C water up
to the knee for 2 min. Anaesthesia was maintained for up to
180 min post-injury. Following intraperitoneal sodium pen-
tobarbital, animals were either transcardially perfused with
saline then 4% paraformaldehyde or the L4–L5 dorsal root
ganglia (DRGs) were dissected from both the ipsilateral and
contralateral sides. ProTxII (0.1 mg/kg; Tocris) or morphine
(3 mg/kg; Sigma) was injected intraperitoneally 15 min be-
fore or after the injury.
Western blotting
The protocol included tissue homogenisation with a pestle
and mortar in ice-cold RIPA buffer (Amresco) and
protease inhibitor cocktail (Sigma-Aldrich), sonication
for 1 h at 4 °C, spinning for 30 min at 14,000 rpm at
4 °C and denaturing at 95 °C for 5 min. NuPAGE
Novex 4–12% Bis-Tris protein gels (Invitrogen, UK) were
used for separation. After transfer to PVDF membranes
(Invitrogen, UK), samples were incubated in 5% non-fat
milk powder (Sigma, UK) for 1 h at room temperature,
then in anti-Nav1.7 and anti-β-tubulin III antibodies at
4 °C overnight followed by incubation in secondary anti-
bodies at room temperature for 1 h and visualisation with
the Luminol kit (Santa Cruz, USA; Supplementary
Table 2). Membranes were examined in a G:Box
(SynGene, UK) using the GeneSnap software package
(Synoptics Ltd, SynGene). Analysis was done by
ImageJ; Nav1.7 intensities were normalised to β-tubulin
intensities in each of the 16 samples (samples from the
ipsilateral and contralateral sides of 8 animals). Then, the
ratio of the normalised intensities found on the ipsilateral
and contralateral sides in each animal was calculated and
averaged.
Immunolabelling
The L4–L5 segments of the spinal cord and the L4 and L5
DRGs were dissected, post-fixed overnight in 4% parafor-
maldehyde and cryoprotected in 30% sucrose. Ten-
micrometre sections were cut and incubated in PBS con-
taining 0.3% Triton-X 100 (PBST) for 10 min, then in
10% normal donkey serum (NDS) for 1 h followed by
the primary antibody (Supplementary Table 1). For visu-
alisation of the phosphorylated serine 10 in histone H3 (p-
S10H3) staining, the tyramide signal amplification proce-
dure was used [12]. Other immunoreactions were
visualised by Alexa Fluor-conjugated secondary antibod-
ies (Supplementary Table 1). Slides were coverslipped
with Vectashield (Vector Laboratories, UK) and examined
with a Leica microscope attached to a Hamamatsu colour-
chilled 3CCD camera.
In vitro electrophysiology
The spinal cord slices were prepared using sham-injured and
burn-injured Wistar rats as described previously [13]. One
hour after the injury, 300-μm transverse slices were cut and
incubated in dissection solution ((in mM) 95 NaCl, 1.8 KCl, 7
MgSO4, 0.5 CaCl2, 1.2 KH2PO4, 26 NaHCO3, 25 D-glucose
and 50 sucrose) for 30 min at 35 °C, stored in a recording
solution ((in mM) 127 NaCl, 1.8 KCl, 1.2 KH2PO4, 2.4
CaCl2, 1.3 MgSO4, 26 NaHCO3 and 25 D-glucose) at room
temperature (21–24 °C) and allowed to recover for at least 1 h
before recordings. All extracellular solutions were saturated
with carbogen (95% O2, 5% CO2).
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Whole-cell patch-clamp recordings (at 21–24 °C) were per-
formed from the superficial dorsal horn neurons clamped at
− 70 mV in the presence of 10 μM bicuculline and 5 μM
strychnine in the bath solution as described previously [13].
The intracellular pipette solution contained (in mM) 125
gluconic acid lactone, 15 CsCl, 10 EGTA, 10 HEPES, 1
CaCl2, 2 Mg2ATP and 0.5 NaGTP and was adjusted to
pH 7.2 with CsOH. An Axopatch 1D (Axon Instruments,
USA) amplifier, a Digidata 1440A digitizer (Molecular
Devices, USA) and the pCLAMP 10.5 software package were
used for recordings. Low-pass filter (2 kHz), 10-kHz sampling
rate and 80% series resistance compensation were used.
Spontaneous excitatory post-synaptic currents (sEPSCs) with
an amplitude of 5 pA or greater (at least twice of the noise)
were included in the frequency and amplitude analyses. Basal
activity recording was followed by recoding in the presence of
ProTxII (10 nM in 0.1% BSA, Tocris) for 5 min. In the end of
the recording protocol, capsaicin (200 nM) was applied to find
whether the neuron received nociceptive input.
Statistical analysis
Data were analysed as previously reported [12]. In brief, pow-
er calculations were used to estimate sufficient sample size
using an online-based software (http://homepage.stat.uiowa.
edu/~rlenth/Power/) and statistical analyses were carried out
using the SPSS program (IBM SPSS statistics 22.0 for
Windows). Data from immunostaining were analysed using
a generalised linear model (GzLM), with significance
assessed with the Wald chi-squared test. For Western blotting,
independent t tests were used. In all cases, differences were
regarded significant at p < 0.05. The statistical significance of
ProTxII on sEPSCs was tested using paired t test and t test
with Bonferroni correction for multiple comparisons. The
sEPSC frequency after ProTxII application was also normal-
ised against the pre-application control value. Data are
expressed as mean ± standard error of mean; n refers to the
number of biological repetitions.
Results
Antibody specificity
In our pilot experiments, we tested several anti-Nav1.7
antibodies and immunolabelling procedures on sections
cut from rat L4 and L5 DRGs. While all the antibodies
provided similar staining pattern, the antibody supplied by
Millipore (Supplementary Table 1) and the procedure de-
scribed above produced the highest signal-to-noise ratio,
which we found suitable for quantitative analysis.
In WT mice, a significant proportion of neurons ap-
peared immunopositive in the cytoplasmic compartment
as well as in the cytoplasmic membrane (Fig. 1a). In con-
trast, only a few immunopositive neurons were apparent
in sections cut from Nav1.7-cKO mouse DRG (Fig. 1b).
The presence of a l imi ted number of Nav1.7-
immunopositive neurons was expected in Nav1.7-cKO
mouse DRG, as neurons that do not express Nav1.8 may
express Nav1.7 [14]. No immunostaining was observed in
negative controls either when the primary antibody was
replaced by normal serum on sections cut from WT
mouse DRGs (data not shown) or when it was exhausted
with the immunising peptide.
In rat L4–L5 DRGs, a significant proportion of neurons
exhibited immunostaining (Fig. 1c). No immunopositive
neurons were visible when the primary antibody was re-
placed by normal serum (data not shown) or exhausted
with the immunising peptide (Supplementary Fig. 1a). In
the positive control, an already characterised antibody
Fig. 1 The anti-Nav1.7 antibody specifically identifies a sub-population
of primary sensory neurons. a Incubation with the anti-Nav1.7 antibody
(Millipore, AB5390) results in immunostaining in a group of primary
sensory neurons in wild-type (WT) mice. Asterisks indicate
immunopositive neurons. b The same anti-Nav1.7 antibody produced
only faint staining in very few neurons in sections cut from the dorsal
root ganglia dissected from mice lacking Nav1.7 (KO; asterisks). c The
anti-Nav1.7 antibody also produces immunostaining in rat primary sen-
sory neurons. Immunopositive cells are indicated by asterisks. d Cell size
distribution of Nav1.7+ neurons in the L4 and L5 dorsal root ganglia of
naive Sprague-Dawley rats. Note that most of the Nav1.7+ neurons are
small- and middle-size cells. Empty bars indicate size distribution of all
cells whereas red bars indicate the size distribution of neurons exhibiting
Nav1.7 immunopositivity. Though we have not tested the expression of
functional Nav1.7, the specificity and selectivity of the antibody suggest
the expression of such functional channels. Scale bar = 50 μm on each
microphotographs (Color figure online)
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(anti-TRPV1 antibody; [15]) showed the characteristic
immunopositivity (Supplementary Fig. 1b).
Nav1.7 immunopositivity was found in about 25% of
the neurons in naive rat DRGs (25.69 ± 6.03%, n = 4).
The size distribution confirmed that Nav1.7 is expressed
predominantly in small- and medium-size neurons (Fig.
1d). The average area of the Nav1.7-immunopositive neu-
rons was significantly smaller than that of the Nav1.7-
immunonegative cells (positive 406.14 ± 33.64 μm2,
n = 4; negative 572.10 ± 33.33 μm2, n = 4; p = 0.0128,
GzLM).
Burn injury upregulates Nav1.7 expression in primary
sensory neurons
Western blots of protein extracts from the ipsi- and contralat-
eral DRGs of rats 5 min and 3 h after the induction of the burn
injury showed the presence of two proteins corresponding to
Nav1.7, at ~ 130 and ~ 210 kDa molecular masses (Fig. 2a)
[16, 17]. Analysis of the Western blots revealed a significant
increase in ipsilateral/contralateral ratio of Nav1.7 protein ex-
pression at 3 h post-injury (Fig. 2a, b), but not at the 5-min
post-injury time point (Fig. 2b, Supplementary Fig. 2; 3 h
1.23 ± 0.09, n = 4; 5 min 0.94 ± 0.02, n = 4, p = 0.041,
Student’s t test).
Quantification of Nav1.7-immunopositive neurons at vari-
ous time points after the injury confirmed the upregulation of
Nav1.7 expression in ipsilateral DRG at 3 h post-injury (naive
25.69 ± 6.03%, 3 h 55.81 ± 14.11%, n = 4 for each; p = 0.05,
GzLM; Fig. 2c). However, no increase in the proportion of
Nav1.7-immunopositive DRG neurons in contralateral DRGs
at any time point following burn injury (not shown) or at either
side following a sham injury was found (naive 25.08 ± 2.97%,
n = 4, p = 0.693; sham ipsilateral 25.72 ± 9.81%, n = 4,
p = 0.797; sham contralateral 27.67 ± 5.97%, n = 4,
p = 0.857; 5 min 22.24 ± 2.57%, n = 4, p = 0.747; 30 min
40.05 ± 9.55%, n = 4, p = 0.185; 1 h 22.32 ± 8.28%, n = 4,
p = 0.753; 3 h 18.96 ± 9.18%, n = 4, p = 0.532; GzLM).
p-CREB is a marker for neuronal activation by burn
injury
Phosphorylated CREB (p-CREB) is a common down-
stream effector of various pathways implicated in regu-
lating transcriptional changes associated with use-
dependent increase in the activity and excitability
(sensitisation) of primary sensory neurons by noxious
stimuli [18]. Hence, we assessed whether p-CREB iden-
tifies activated primary sensory neurons in our burn inju-
ry model.
p-CREB expression exhibited a biphasic increase in pri-
mary sensory neurons following burn injury; at 5 min post-
injury, p-CREB appeared in the nuclear compartment of
small- and medium-size neurons (5 min 10.98 ± 3.16%,
n = 4; naive 0.41 ± 0.41%, n = 4, p < 0.001; GzLM;
Fig. 3a–d). Following a rapid return to baseline expression
Fig. 2 Burn injury induces upregulation in Nav1.7 expression. a A
gel image of Western blotting using the anti-Nav1.7 and anti-β-
tubulin III antibodies with protein samples isolated from the ipsilat-
eral (ipsi) and contralateral (contra) L4 and L5 dorsal root ganglia of
a rat 180 min after burn injury. Note that both antibodies produced
double blots; consistent with previous findings, Nav1.7 is expressed
at ~ 135 and 210 kDa (indicated by an arrowhead), whereas β-
tubulin III expression is between 50 and 60 kDa. Both Nav1.7 bands
were considered for analysis. b Ratios between normalised Nav1.7
expression found in the contra- and ipsilateral L4–L5 dorsal root
ganglia 5 and 180 min after burn injury reveal that burn injury
induces upregulation in Nav1.7 expression. n = 4. *p < 0.05. c
Quantification of Nav1.7 immunostaining in L4–L5 dorsal root gan-
glia confirms upregulation of Nav1.7 expression at 180 min after
burn injury. n = 4. *p < 0.01
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level (30 min 2.95 ± 2.68%, n = 4, p = 0.393; 60 min
3.85 ± 2.38%, n = 4, p = 0.287; GzLM), the proportion
of p-CREB-expressing neurons was significantly increased
again at 3 h post-injury (3 h 6.10 ± 2.41%, n = 4, p = 0.041
vs naive, p = 0.097 vs. 5 min, GzLM; Fig. 3d). The major-
ity of neurons exhibiting immunopositivity for p-CREB
were small- and medium-size neurons (Fig. 3e; positive
3 6 4 . 6 1 ± 5 0 . 7 8 μ m 2 , n = 4 ; n e g a t i v e :
506.51 ± 26.69 μm2, n = 4; p = 0.001, GzLM). In addition
to primary sensory neurons, p-CREB was also present in
the nuclei of some satellite cells 5 min after the burn injury.
However, further investigation of this expression was out-
side the scope of this study; therefore, we did not analyse
satellite cell expression of p-CREB any further.
Fig. 3 Burn injury induces upregulation in p-CREB expression in
Nav1.7-expressing primary sensory neurons in L4–L5 dorsal root ganglia.
a L4–L5 dorsal root ganglia dissected from naive rats contain virtually no
neurons which express p-CREB in their nuclei. b Burn injury induces p-
CREB expression in a significant number of primary sensory neurons in
the ipsilateral L4–L5 dorsal root ganglia. Arrows indicate p-CREB-
immunopositive nuclei. c Combined immunostaining with the anti-
Nav1.7 (green) and the anti-p-CREB (red) antibodies on sections from
the ipsilateral L4–L5 dorsal root ganglia shows that CREB phosphoryla-
tion following burn injury occurs predominantly in Nav1.7-expressing
primary sensory neurons. Arrows show neurons exhibiting double
immunopositivity, whereas asterisks indicate neurons with p-CREB
immunopositivity without expressing Nav1.7. d Quantification of prima-
ry sensory neurons reveals significant upregulation of p-CREB expres-
sion at 5 and 180 min after burn injury in primary sensory neurons in the
ipsilateral L4–L5 dorsal root ganglia. Asterisks indicate statistical signif-
icance. n = 4. e Size distribution of neurons exhibiting p-CREB expres-
sion in the nucleus (red bars) 5 min after the injury reveals that small-
diameter neurons are activated by burn injury. Empty bars indicate all
neurons. f–h Pie charts indicating the proportion of primary sensory neu-
rons exhibiting Nav1.7 and p-CREB co-expression in the ipsilateral L4–
L5 dorsal root ganglia in naive condition, 5 and 180 min after burn injury,
respectively. Scale bar = 50 μm on each microphotograph (Color figure
online)
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p-CREB is expressed in Nav1.7-expressing neurons
Double immunostaining revealed that while in the naive
rats, about 25% of the very few cells with p-CREB-
i mm u n o p o s i t i v e n u c l e i e x h i b i t e d N a v 1 . 7
immunopositivity, 5 min after the burn injury, ~ 90% of
the cells with p-CREB-immunopositive nuclei also exhib-
ited immunopositivity for Nav1.7 (87.5 ± 7.98%, n = 4;
Fig. 3c, f, g). The co-expression pattern was very similar
at 3 h post-injury (p = 0.983; Fig. 3h).
Very few Nav1.7-immunopositive neurons showed p-
CREB immunopositivity in naive animals (13.3 ± 3.33%,
n = 4). The co-expression pattern increased to around 80%
5 min after the burn injury (77.58 ± 10.16%, n = 4), and this
propor t ion remained s imi la r a t 3 h pos t - in ju ry
(63.42 ± 10.31%, n = 4; p = 0.758).
Together, these data support recent reports on the pivotal
role of Nav1.7 in the development of burn injury-associated
pain [4]. Those reports also showed that Nav1.7 is particularly
important in the development of burn injury-associated heat
hyperalgesia [4]. We have shown most recently that burn in-
jury induces a rapid and sustained upregulation of p-S10H3 in
a sub-population of spinal dorsal horn neurons [12]. Our find-
ings also indicate that p-S10H3 can be used as a marker for
nociceptive activation of spinal cord neurons involved in the
development of inflammatory heat hyperalgesia [12].
Therefore, next, we assessed the effect of blocking Nav1.7
on p-S10H3 expression in the spinal dorsal horn.
Nav1.7 blockade partially reduces burn injury-induced
nociceptive activation in spinal cord neurons
Burn injury induced a significant increase in the number of
neurons with nuclei immunopositive for p-S10H3 in the ipsi-
lateral spinal dorsal horn at 60 min post-injury (60 min
30.00 ± 1.73, n = 3; control: 2.33 ± 0.88, n = 3; p < 0.001,
GzLM; Fig. 4a, b, g). Neurons exhibiting nuclei with p-
S10H3 immunopositivity were distributed among Nav1.7-
immunopos i t ive f ibres (Supplementary Fig. 3) .
Intraperitoneal injection of ProTxII 15 min before the injury
significantly reduced the number of pS10H3-positive nuclei in
the ipsilateral spinal dorsal horn (Fig. 4a–c, g; ProTxII-before
12.33 ± 1.45, n = 3, p < 0.001, GzLM). ProTxII, injected
15 min after the injury, also significantly reduced the number
of neurons exhibiting p-S10H3 expression in the ipsilateral
spinal dorsal horn (Fig. 4a, b, d, g; ProTxII-after:
11.33 ± 1.20, n = 3, p < 0.001, GzLM). There was no differ-
ence between the reductions produced by protoxin injection
before or after the injury (p = 0.491, GzLM; Fig. 4g).
Morphine injection 15 min before the injury completely
prevented the upregulation of p-S10H3 expression by burn
injury (morphine-before 1.66 ± 0.88, n = 3, p = 0.646,
GzLM; Fig. 4a, b, e, g). Morphine, injected 15 min after the
induction of the burn injury, significantly reduced the number
of neurons exhibiting p-S10H3-immunopositive nuclei (mor-
phine-after 11.33 ± 1.20, n = 3, p < 0.001, GzLM; Fig. 4a, b, f,
g). The number of activated neurons found in the morphine-
after group was not significantly different from that found in
naive animals. Both ProTxII and morphine had similar effects
on the expression of phosphorylated ERK (p-ERK) 1/2 in the
spinal cord (Supplementary Fig. 4).
ProTxII reduces sEPSC frequency following burn injury
To confirm that ProTxII reduces spinal nociceptive processing
in burn injury, we also assessed the effect of ProTxII on
sEPSCs in the spinal superficial dorsal horn neurons. sEPSC
frequency in sham-operated animals was 0.8 ± 0.2 Hz (n = 9),
and ProTxII (10 nM) did not change that (99.7 ± 8.7% of the
control value; Fig. 5a, b). sEPSC amplitudes in naive slices
were − 14.7 ± 2.0 pA before and − 15.1 ± 2.2 pA after the
ProTxII. All the tested neurons responded to capsaicin
(200 nM; 25.6 ± 5.7 Hz, n = 8; p = 0.003).
sEPSC frequency exhibited a robust and significant in-
crease following burn injury (3.1 ± 0.6 Hz; Fig. 5a, b,
p = 0.002). ProTxII significantly decreased the sESPC fre-
quency to 2.1 ± 0.5 Hz (66.2 ± 8.1% of the control value;
Fig . 5a , b) . The average sEPSC ampl i tude was
− 17.8 ± 3.4 pA, and ProTxII did not change that
(− 17.1 ± 3.6 pA). All neurons responded to capsaicin
(31.5 ± 7.1 Hz; n = 10; p = 0.003). The capsaicin response
was not different in the sham and injured groups.
Discussion
Similar to previous reports, we found that a significant pro-
portion of primary sensory neurons express Nav1.7 [5, 17].
While we did not test whether Nav1.7 is functional in the
Nav1.7-expressing primary sensory neurons, previous find-
ings that a significant proportion of primary sensory neurons
do express such currents [4, 5, 14, 17, 19] indicate that at least
a proportion of the Nav1.7-immunopositive neurons express
functional Nav1.7 channels.
Both Western blotting and immunostaining revealed that
Nav1.7 expression is increased in DRGs by 3 h post-injury.
Similar upregulation has been reported in other peripheral
inflammatory models [20, 21]. Increased density of Nav1.7-
mediated currents in primary sensory neurons following burn
injury was also reported recently [4]. The increased Nav1.7
expression and the increased density of Nav1.7-mediated cur-
rents, 3 h and 2 days after the injury, respectively, support the
view that Nav1.7 significantly contributes in enhancing noci-
ceptive signalling of primary sensory neurons during the en-
tire course of burn injury [4].
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Burn injury induced a biphasic upregulation in the expres-
sion of p-CREB, a marker for neurons activated by various
painful peripheral pathologies, including inflammation of var-
ious origins in primary sensory neurons [18, 22]. The increase
at 5 min could be due to the activation of neurons by the
excessive heat and/or molecules released from the
degenerated cells. The increase at 180 min could be due to
the activation of neurons by inflammatory mediators [1].
Importantly, we found a high degree of co-expression between
Nav1.7 and p-CREB after burn injury indicating that Nav1.7-
expressing neurons are activated by this injury.
We analysed p-ERK 1/2 and p-S10H3 expressions to find
the effect of morphine and ProTxII on spinal nociceptive
processing. While p-ERK1/2 is well-established, p-S10H3 is
a novel marker for nociceptive activation of spinal dorsal horn
neurons [11, 12, 23]. As confirmed in the present study, burn
injury induces sustained upregulation in both p-ERK1/2 and
p-S10H3 expressions in the spinal dorsal horn [11, 12].
Both morphine and ProTxII, which respectively activates
the μ-opioid receptors (MOR; [24]) and inhibits Nav1.7 [10],
significantly reduced the burn injury-induced upregulation of
both p-ERK1/2 and p-S10H3 expressions. While the finding
that morphine reduces spinal nociceptive processing is in full
agreement with a large body of previous findings [25, 26], the
effect of ProTxII appears to be in contrast to previous reports
that intravenous or intrathecal ProTxII injection does not
Fig. 4 Intraperitoneal injection of protoxin II or morphine reduces burn
injury-induced upregulation of p-S10H3 expression in the ipsilateral spi-
nal dorsal horn. a–f p-S10H3 expression in the ipsilateral spinal dorsal
horn in naive condition (a), 60 min after burn injury (b), with the injection
of protoxin II 15 min before (c) or 15 min after (d) the injury and with the
injection of morphine 15 min before (e) or 15 min after (f) the injury.
Dashed lines indicate the border of the spinal cord, whereas dotted lines
indicate the white-grey matter border. Note that burn injury induces up-
regulation in the expression of p-S10H3, whereas either protoxin II or
morphine reduces that upregulation irrespective of whether the drug is
given before or after the injury. g Quantification of neurons exhibiting p-
S10H3 expression in various conditions. Asterisk indicates significant
difference in the number of p-S10H3-expressing nuclei between naive
condition and 60 min after burn injury, whereas plus signs indicate sig-
nificant difference in the number of p-S10H3-expressing nuclei between
60 min after burn injury and various treatments. Scale bar = 100 μm on
each image
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reduce pain-related behaviour [10]. Although due to animal
welfare considerations, we did not assess pain-related behav-
iour, the similar magnitude of inhibitory effects by morphine
and ProTxII administration following the injury suggests that
similar to morphine [27], ProTxII is also highly likely to pro-
duce an analgesic effect.
The lack of effect by ProTxII on pain-related behaviour
was attributed to the inability of the toxin to access Nav1.7
in intact peripheral nerves and to pass the blood-brain barrier
[10, 28]. However, a recent finding has demonstrated that
ProTxII can access Nav1.7 in the spinal cord following intra-
thecal delivery as well as the peripheral nerve after perineural
application [29]. Our data suggest that in addition to those,
ProTxII may also reach Nav1.7 following intraperitoneal in-
jection. While we did not assess the site of action, based on
previous findings, we propose that the ProTxII-produced in-
hibitory effect on spinal nociceptive processing could be due
to ProTxII-induced inhibition of Nav1.7 expressed on free
nerve endings at the injured tissues as well as the central ter-
minals of Nav1.7-expressing primary sensory neurons.
The significantly larger effect of morphine than of
ProTxII on the upregulation of both p-S10H3 and p-
ERK1/2 when applied before the injury could be due to
the differing respective access to MOR and Nav1.7 of
morphine and ProTxII in various parts of primary sensory
neurons in naive conditions [25, 26].
The effect of morphine or ProTxII applied 15 min after
the injury that models the time course of burn-injured
patients receiving analgesics for the first time shows that
both drugs are able to induce a significant downregulation
in the expression of both markers, hence reducing spinal
nociceptive processing. Interestingly, ProTxII produces a
greater downregulation in p-S10H3 than p-ERK1/2 ex-
pression, which could be due to both Nav1.7 and p-
S10H3 being involved in the development of heat hyper-
sensitivity [4, 7, 8, 12], whereas p-ERK1/2 is involved in
the development of both thermal and mechanical hyper-
sensitivities [23]. Nevertheless, the downregulation of p-
ERK1/2 and p-S10H3 by morphine or ProTxII 15 min
after the injury indicates that ongoing activity of MOR-
and/or Nav1.7-expressing primary sensory neurons is
needed for the nociceptive activation of the spinal dorsal
horn neurons in burn injury.
Our electrophysiological recordings confirm the significant
role of Nav1.7 in spinal nociceptive processing following burn
injury. Burn injury significantly increased sEPSC frequency
which was significantly reduced by ProTxII. The differential
effect of ProTxII in naive slices and slices prepared after burn
injury could be due to Nav1.7 playing a minor role, whereas it
gains a much more prominent role in generating spontaneous
activity of nociceptive primary sensory neurons in naive con-
dition and after burn injury, respectively. Alternatively,
ProTxII, due to neuroinflammatory processes in the spinal
cord, may have access to Nav1.7 on the central terminals of
the primary sensory neuron after burn injury.
Morphine or other opioids used currently to control pain in
burn-injured patients induce a series of undesirable effects
[30, 31]. Based on the similar effects of morphine and
ProTxII on p-ERK1/2 and p-S10H3 expressions by the spinal
dorsal horn neurons and the role of p-ERK1/2 and p-S10H3 in
the development of persistent pain associated with peripheral
pathologies [11, 12, 32, 33], we propose that blocking Nav1.7
could reduce pain, particularly heat hyperalgesia [4, 7, 8], in
Fig. 5 ProTxII significantly reduces sEPSC frequency following burn
injury. The effect of ProTxII sEPSC frequency recorded from the spinal
superficial dorsal horn neurons. In the slices with the sham treatment
(n = 9), the basal sEPSC frequency was low and ProTxII (10 nM) did
not produce any change (a, b, sham). Neurons in slices prepared after the
burn injury (n = 10) exhibited a robust increase in sEPSCs (a, burn
injury), and the application of ProTxII induced a significant decrease of
the sEPSC frequency (a, b, **p = 0.006). The basal sEPSC frequency in
the sham group and the burn injury group was significantly different (b,
##p = 0.002)
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burn injury with a potency equivalent to that produced by
morphine.
Previous attempts to recapitulate the profound analge-
sic phenotype of Nav1.7
−/− mice or loss of function hu-
man mutations [5, 19] by pharmacological agents pro-
duced disappointing results [3]. However, a recent report
has shown that a ProTxII-based designer peptide acting
on Nav1.7 is able to reproduce the analgesic phenotype
observed in mice lacking Nav1.7
−/− or humans having a
loss of function Nav1.7 mutations [29]. Therefore, based
on the expression pattern of Nav1.7 [5, 14, 17, 19], it is
likely that blocking Nav1.7, particularly in a cell-specific
manner, could produce a significant analgesic effect with
significantly less undesirable effects than opioids.
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